Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura

被引：7
|
作者：
Aggarwal, Asha [1 ]
White, Danielle [2 ]
Pavord, Sue [1 ]
Thomas, Will [2 ]
Desborough, Michael J. R. [1 ,3 ,4 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Cambridge, England
[3] Univ Oxford, Radcliffe Dept Med, Oxford, England
[4] John Radcliffe Hosp, Dept Clin Haematol, Headley Way, Oxford OX3 9DU, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 202卷 / 02期
关键词：
daratumumab; plasma cell; refractory; thrombotic thrombocytopenic purpura (TTP);
D O I：
10.1111/bjh.18854
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：429 / 433
页数：5
相关论文
共 50 条
  • [31] AlemtuzumabNon-symptomatic Graves' disease and immune-mediated thrombotic thrombocytopenic purpura
    Reactions Weekly, 2024, 2007 (1) : 26 - 26
  • [32] Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod, Adrien
    Veyradier, Agnes
    Coppo, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (01) : 58 - 67
  • [33] IMMUNE-MEDIATED ENDOTHELIAL CELL INJURY IN PATHOGENESIS OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
    WALL, RT
    HARKER, LA
    QUADRACCI, LJ
    STRIKER, GE
    CLINICAL RESEARCH, 1977, 25 (03): : A350 - A350
  • [34] Two pregnant women with immune-mediated thrombotic thrombocytopenic purpura: A case report
    Uchida, Akiko
    Tanimura, Kenji
    Sasagawa, Yuki
    Yamada, Hirotaka
    Katayama, Yoshio
    Matsumoto, Masanori
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2023, 49 (12) : 2969 - 2974
  • [35] Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura
    Jérémie Joffre
    Lisa Raia
    Tomas Urbina
    Vincent Bonny
    Paul Gabarre
    Louai Missri
    Jean-Luc Baudel
    Paul Coppo
    Bertrand Guidet
    Eric Maury
    Hafid Ait-Oufella
    Critical Care, 27
  • [36] Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Kuehne, Lucas
    Eichenauer, Dennis A.
    Knoebl, Paul
    Voelker, Linus A.
    Kaufeld, Jessica
    Wendt, Ralph
    Haegele, Holger
    Osterholt, Thomas
    Bieringer, Marcus
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Schoenermarck, Ulf
    Brinkkoetter, Paul
    BLOOD, 2021, 138
  • [37] Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
    Giannotta, Juri Alessandro
    Artoni, Andrea
    Mancini, Ilaria
    Agosti, Pasquale
    Carpenedo, Monica
    Truma, Addolorata
    Miri, Syna
    Ferrari, Barbara
    De Leo, Pasqualina
    Salutari, Prassede
    Mancini, Giorgia
    Molteni, Alfredo
    Rinaldi, Ermina
    Bocchia, Monica
    Napolitano, Mariasanta
    Prezioso, Lucia
    Cuccaro, Annarosa
    Scarpa, Elisabetta
    Condorelli, Annalisa
    Grimaldi, Daniele
    Massaia, Massimo
    Peyvandi, Flora
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025, 23 (02) : 704 - 716
  • [38] Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura
    Joffre, Jeremie
    Raia, Lisa
    Urbina, Tomas
    Bonny, Vincent
    Gabarre, Paul
    Missri, Louai
    Baudel, Jean-Luc
    Coppo, Paul
    Guidet, Bertrand
    Maury, Eric
    Ait-Oufella, Hafid
    CRITICAL CARE, 2023, 27 (01)
  • [39] Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura
    Brodsky, Max A.
    Sukumar, Senthil
    Selvakumar, Sruthi
    Yanek, Lisa
    Hussain, Sarah
    Mazepa, Marshall A.
    Braunstein, Evan M.
    Moliterno, Alison R.
    Kickler, Thomas S.
    Brodsky, Robert A.
    Cataland, Spero R.
    Chaturvedi, Shruti
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (12) : 1587 - 1594
  • [40] How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge
    Akwaa, Frank
    Antun, Ana
    Cataland, Spero R.
    BLOOD, 2022, 140 (05) : 438 - 444
12345